Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.913 EUR | +0.88% | -5.19% | -16.08% |
04-30 | Sweden’s Competition Watchdog Prohibits Oriola's Dose Dispensing Unit Sale | MT |
04-25 | Transcript : Oriola Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
Strengths
- The stock, which is currently worth 2024 to 0.1 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Sales forecast by analysts have been recently revised upwards.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.08% | 185M | B- | ||
-1.88% | 24.09B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.97B | B- | ||
-4.06% | 7.84B | C | ||
+2.26% | 4.66B | B- | ||
+17.12% | 4.32B | B+ | ||
+1.41% | 4.19B | B- | ||
-3.02% | 3.89B | B | ||
+21.42% | 3.62B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OKDBV Stock
- Ratings Oriola Oyj